Literature DB >> 2873846

Specific somatostatin-binding to cytosol of bovine gallbladder mucosa.

E Arilla, B Colás, J C Prieto.   

Abstract

The binding of somatostatin was studied in the cytosolic fraction of bovine gallbladder mucosa. The binding reaction depended on time, temperature and pH, and was reversible, saturable and specific. Stoichiometric data suggested the presence of two classes of binding sites: a class with high affinity (Kd = 23.6 nM) and low capacity (3.7 pmol somatostatin/mg protein) and a class with low affinity (Kd = 284.6 nm) and high capacity (85.0 pmol somatostatin/mg protein) at 37 degrees C and pH 7.4. The binding sites were highly specific for somatostatin since peptides such as [Leu]enkephalin, neurotensin, vasoactive intestinal peptide and substance P showed practically no effect upon somatostatin binding. The presence of somatostatin-binding sites in the cytosolic fraction of gallbladder mucosa, together with the known occurrence of somatostatin nerve endings in the gallbladder strongly suggests that this peptide may be involved in the physiology and physiopathology of gallbladder mucosa.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2873846     DOI: 10.1007/bf01115157

Source DB:  PubMed          Journal:  Biosci Rep        ISSN: 0144-8463            Impact factor:   3.840


  3 in total

1.  Effect of small doses of somatostatin analog, octreotide, on gallbladder contractility in normal Chinese adults.

Authors:  X F Zhu; Y F Shi; J X Zhang; A G Harris
Journal:  Dig Dis Sci       Date:  1992-01       Impact factor: 3.199

2.  Effect of octreotide on dynamic excretion of bile in Chinese acromegalic patients assessed by [99mTc]EHIDA hepatobiliary scan.

Authors:  X F Zhu; A G Harris; M F Yang; Y F Shi; Q Zhou; J Y Xu; J X Zhang
Journal:  Dig Dis Sci       Date:  1994-02       Impact factor: 3.199

3.  Effects of somatostatin and loxiglumide on gallbladder motility.

Authors:  R J Lieverse; J B Jansen; M C Jebbink; A A Masclee; L C Rovati; C B Lamers
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.